Freestone Grove Partners LP Ultragenyx Pharmaceutical Inc. Transaction History
Freestone Grove Partners LP
- $13.4 Trillion
- Q3 2025
A detailed history of Freestone Grove Partners LP transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 18,639 shares of RARE stock, worth $616,578. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,639Holding current value
$616,578% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RARE
# of Institutions
351Shares Held
88.3MCall Options Held
2.23MPut Options Held
1.06M-
Vanguard Group Inc Valley Forge, PA10.1MShares$335 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$185 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY4.01MShares$133 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.77MShares$125 Million0.33% of portfolio
-
State Street Corp Boston, MA3.69MShares$122 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.32B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...